IN VİTRO ANTİTUMOR EFFECTS OF A NEW CULTİVAR (GÜRARSLAN) OF TRİGONELLA FOENUM GRAECUM L.

Background: The main goals of our study were as follows: (1) to investigate whether the methanolic extract of the new cultivar (Gürarslan) of Trigonella foenum graecum L. seeds exhibit antiproliferative effects on the HeLa human cervix carcinoma, Mat-LyLu rat prostate carcinoma and 3T3 embryonic mouse fibroblast cell lines, (2) to determine how mitosis and DNA synthesis are affected in cancer cells by the extract, and (3) to observe the changes in cell morphology after treatment with the extract. Materials and Methods: The effect on cell proliferation of these extracts was detected by using methyl thiazolyl diphenyl tetrazolium (MTT) assay. Mitotic index and labelling index was determined using the Feulgen staining and autoradiography methods, respectively. Results: Our findings show that the methanolic extract of T. foenum graecum seeds might have antiproliferative properties on the cancer cell lines only, but not on the 3T3 embryonic mouse fibroblast cell line. Conclusion: Our data show that the new variety of T. foenum graecum may have antitumoral properties

EPIdemiology of Surgery-Associated Acute Kidney Injury (EPIS-AKI) : Study protocol for a multicentre, observational trial

More than 300 million surgical procedures are performed each year. Acute kidney injury (AKI) is a common complication after major surgery and is associated with adverse short-term and long-term outcomes. However, there is a large variation in the incidence of reported AKI rates. The establishment of an accurate epidemiology of surgery-associated AKI is important for healthcare policy, quality initiatives, clinical trials, as well as for improving guidelines. The objective of the Epidemiology of Surgery-associated Acute Kidney Injury (EPIS-AKI) trial is to prospectively evaluate the epidemiology of AKI after major surgery using the latest Kidney Disease: Improving Global Outcomes (KDIGO) consensus definition of AKI. EPIS-AKI is an international prospective, observational, multicentre cohort study including 10 000 patients undergoing major surgery who are subsequently admitted to the ICU or a similar high dependency unit. The primary endpoint is the incidence of AKI within 72 hours after surgery according to the KDIGO criteria. Secondary endpoints include use of renal replacement therapy (RRT), mortality during ICU and hospital stay, length of ICU and hospital stay and major adverse kidney events (combined endpoint consisting of persistent renal dysfunction, RRT and mortality) at day 90. Further, we will evaluate preoperative and intraoperative risk factors affecting the incidence of postoperative AKI. In an add-on analysis, we will assess urinary biomarkers for early detection of AKI. EPIS-AKI has been approved by the leading Ethics Committee of the Medical Council North Rhine-Westphalia, of the Westphalian Wilhelms-University Münster and the corresponding Ethics Committee at each participating site. Results will be disseminated widely and published in peer-reviewed journals, presented at conferences and used to design further AKI-related trials. Trial registration number NCT04165369

The Role of Lidocaine in the Dunning Model Rat Prostate Cancer Cells: Cell Kinetics and Motility

Deaths resulting from prostate cancer are due to metastases rather than primary tumor. Therefore, understanding metastatic mechanisms play a significant role. It has been determined that metastatic progression can be avoided by the voltage-gated sodium channels (VGSCs) in cell membranes. We aimed to evaluate the effects of Lidocaine, a VGSC blocker, on the cell proliferation of rat prostate cancer cells (Mat-LyLu and AT-2) and the lateral motility, which indicates metastases. The effect of lidocaine at different concentrations (0.1–10 mM) on the proliferation of cells was determined by the MTT method, and the effects on DNA synthesis was determined by the autoradiography. Motility of cells was realized with the wound heal method, and tetrodotoxin was used as the positive control. We have obtained, lidocaine decreased the proliferations of high metastatic Mat-LyLu cells and low metastatic AT-2 cells from 0.5 mM and 1 mM, respectively. Labeling index results are also parallel with proliferation results. While lidocaine decreased the motility of Mat-LyLu cells expressing Nav.1.7 VGSC (p < 0.05), it did not cause a change in the motility of AT-2 cells. It has been demonstrated for the first time that lidocaine has the potential to be used as an ion channel blocker in rat prostate cancer metastases